Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Coblopasvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Beijing Kawin Technology Share-Holding Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Coblopasvir is a once-a-day capsule for adults with long-term (chronic) hepatitis C. It is made in Beijing by Kawin Technology and sold in China under the brand name 凯力唯 (Kailiwei®); during development it was known as KW-136. It never works alone: the label pairs it with sofosbuvir, and the two are taken together for 12 weeks with the aim of clearing the virus.
China's National Medical Products Administration (NMPA) approved the capsule on 11 February 2020, after a priority review. According to the Chinese label, it is used together with sofosbuvir for adults with:
It is a prescription liver disease medicine, so a hepatologist or gastroenterologist should decide whether it suits you.
Hepatitis C needs a viral protein called NS5A to copy its genetic material and assemble new virus particles. This medicine is an NS5A inhibitor: it binds that protein and stops the copying process. Sofosbuvir blocks a different viral enzyme (NS5B), so the virus is attacked at two points at once. In laboratory tests the capsule was active against genotypes 1 to 6, though the approved uses cover genotypes 1, 2, 3 and 6.
The approval rested mainly on a phase 3 study at 19 hospitals in China, published in Liver International in 2020. 371 adults took 60 mg of the capsule with sofosbuvir 400 mg daily for 12 weeks. Overall, 97% (359 of 371) were still free of the virus in blood tests three months after finishing (SVR12, the standard measure of cure). By genotype, the cure rates were 99% for genotype 1, 96% for genotype 2, 90% for genotype 3 and 98% for genotype 6. Among people with advanced fibrosis or compensated cirrhosis it was 97%, and all 39 patients treated earlier with interferon were cured. Ten patients (3%) saw the virus return after finishing.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: anyone allergic to the capsule or its ingredients. Because it is always combined with sofosbuvir, the warnings and contraindications of sofosbuvir apply to the whole course as well.
Side effects in the phase 3 study: no treatment-related side effect affected more than 5% of patients, and all were mild or moderate. The most frequent were a fall in neutrophils (a type of white blood cell, 3.8%), weakness (3.0%), low blood albumin (2.7%), headache (1.9%), dizziness, diarrhoea and raised uric acid (1.6% each), low platelets (1.3%), and nausea, stomach pain and fatty liver (1.1% each). Twelve patients (3.2%) had a serious health event, judged by the investigators as unrelated or unlikely to be related to the medicines; no one stopped treatment because of side effects and no one died.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can only be imported in the name of the patient who will take them, by the patient or a government hospital, under India's regulations on importing unapproved medicines. Please have these ready:
After our team has reviewed the prescription and the import permit, where one is needed.
No. It is registered in China only. India's CDSCO has not approved it, so Indian pharmacies do not stock it, and neither the US FDA nor the European Medicines Agency has approved it.
It can still be obtained legally through the Named Patient Program (NPP), which permits a medicine without Indian registration to be imported for a single named patient on a doctor's prescription. We also arrange other China-approved hepatitis C medicines, such as netanasvir capsules and alfosbuvir tablets, when a specialist prescribes them.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The Chinese label asks for storage in a closed pack at no more than 30°C, so the capsules move in sealed original boxes under temperature-controlled shipping. Boxes come in several sizes; the largest holds 12 blister strips of 7 capsules, which is 84 capsules, enough for one full 12-week course at one capsule a day. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
These capsules travel well at room temperature, so we can send them to almost any Indian city once a hepatologist or gastroenterologist has written the prescription and the import papers are in place.
Hepatitis C patients treated at Delhi liver institutes can receive the full 12-week supply soon after the paperwork clears, since it ships from New Delhi.
Gastroenterologists in Mumbai can send us the genotype and viral load reports, and we confirm what the import needs before quoting.
For patients in Bangalore, delivery can go to the home or to the clinic where the 12-week check-ups take place.
Liver teams in Chennai can plan the start date with us so the capsules arrive before the first day of treatment.
Patients in Hyderabad and across Telangana can request this hepatitis C capsule through the same named-patient route used in other metros.
Families in Kolkata receive a written quote and a delivery estimate before anything is ordered from China.
Patients in Pune are kept informed at each stage, from prescription check to the day the box reaches them.
Hepatologists in Ahmedabad can arrange the import for a named patient and keep the course on schedule with one complete shipment.
Patients in Jaipur and wider Rajasthan can have the capsules sent to them rather than travelling to a metro hospital.
Liver clinics in Chandigarh serving Punjab, Haryana and Himachal Pradesh can have the medicine delivered direct to the clinic.
For patients in Lucknow and across Uttar Pradesh, we coordinate with the treating doctor on the documents needed in the patient's name.
Patients in Kochi and other Kerala towns can receive the sealed boxes at home once the prescription has been verified.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message